Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT

Inclusion Criteria

• •1. Male and Female subjects with CD123+ acute myeloid leukemia as confirmed by immunohistochemistry and flow cytometry;
• •2. Patients must have received an allogenic stem cell transplantation(Allo-HSCT). The leukemia relapsed. There are available donor or enough cryopreserved donor-derived PBMCs for CART preparation and subsequent Allo-HSCT. In the previous case, the donor should have adequate venous access for apheresis.
• •3. Karnofsky score greater than 70%;
• •4. patients more than 18 years of age
• •5. Expected survival time \>16 weeks;
• •6. Bilirubin \<3.0 mg/dL,
• •7. Alanine aminotransferase(ALT)/ aspartate aminotransferase(AST)\<3 fold normal.
• •8. Diffusing capacity of the lung for carbon monoxide(DLCO) and forced expiratory volume in one second(FEV1)\>45% of predictive value.
• •9. At least received three kinds of medicines functioning by different mechanisms, including alkylating agents, protease inhibitors, and immunomodulators, and disease progressing within 60 days.
• •10. Important organs are well tolerated;
• •11. For post-transplantation patients, the apheresis would be undertaken only at least 2 weeks after immunosuppressive agents for GvHD withdrawal;
• •12. From very beginning of the test to 30 days after the withdrawal, men and women should adopt reliable contraceptive measures.
• •13. All research participants must have the ability to understand and willingness to sign a written informed consent.